School of Clinical Medicine, Chengdu Medical College, Chengdu, China.
Department of Clinical Laboratory, The First Affiliated Hospital of Chengdu Medical College, Chengdu, China.
Technol Cancer Res Treat. 2023 Jan-Dec;22:15330338231178391. doi: 10.1177/15330338231178391.
Because lung cancer is the main cause of cancer deaths and lung adenocarcinoma (LUAD) accounts for more than 40% of all lung malignancies, it is essential to develop clinically useful biomarkers for the disease. The aim of this investigation is to assess the potential application of tubulin alpha-1b (TUBA1B) as a biomarker for diagnosing and monitoring the outcome of LUAD. The clinical data of the LUAD patients was retrospectively analyzed. Immunohistochemistry (IHC) analysis of a tissue microarray containing 90 LUAD cases was implemented to examine the expression of TUBA1B. The protein and mRNA levels of TUBA1B in serum were detected by enzyme-linked immunosorbent assay (ELISA) and quantitative real-time PCR (qRT-PCR) analysis respectively. UALCAN was employed to confirm the expression levels and survival probability of TUBA1B in LUAD patients. Compared to adjacent non-cancerous tissues in the microarray, the expression of TUBA1B in LUAD tissues was much higher. The expression of TUBA1B in LUAD was statistically correlated with lymph node status ( = .031). Moreover, patients with higher TUBA1B expression had shorter overall survival ( < .0001). Furthermore, cox multi-factor analysis also suggested that TUBA1B may be an independent predictor for LUAD prognosis ( = .030). The results of TCGA data analysis by UALCAN were consistent with the microarray results, except for that TUBA1B was also significantly correlated with clinical tumor stages. Protein levels of TUBA1B in serum were obviously elevated in LUAD patients than control ( < .0001), and the area under the ROC curve was 0.99. TUBA1B also showed better sensitivity of 92.9% for LUAD than common clinical biomarkers. TUBA1B may be a non-invasive prognostic and diagnostic biomarker for LUAD patients.
由于肺癌是癌症死亡的主要原因，肺腺癌（LUAD）占所有肺癌恶性肿瘤的 40%以上，因此开发用于该疾病的临床有用的生物标志物至关重要。本研究旨在评估微管蛋白α-1b（TUBA1B）作为诊断和监测 LUAD 结果的潜在生物标志物。
回顾性分析了 LUAD 患者的临床数据。通过免疫组织化学（IHC）分析包含 90 例 LUAD 病例的组织微阵列来检测 TUBA1B 的表达。通过酶联免疫吸附测定（ELISA）和定量实时 PCR（qRT-PCR）分析分别检测血清中 TUBA1B 的蛋白和 mRNA 水平。UALCAN 用于确认 LUAD 患者中 TUBA1B 的表达水平和生存概率。
与微阵列中的相邻非癌性组织相比，LUAD 组织中 TUBA1B 的表达明显更高。TUBA1B 在 LUAD 中的表达与淋巴结状态呈统计学相关（=.031）。此外，TUBA1B 表达较高的患者总生存期较短（<.0001）。此外，cox 多因素分析还表明，TUBA1B 可能是 LUAD 预后的独立预测因子（=.030）。UALCAN 对 TCGA 数据分析的结果与微阵列结果一致，但 TUBA1B 也与临床肿瘤分期显著相关。LUAD 患者血清中 TUBA1B 的蛋白水平明显高于对照组（<.0001），ROC 曲线下面积为 0.99。TUBA1B 对 LUAD 的敏感性也优于普通临床生物标志物，为 92.9%。
TUBA1B 可能是 LUAD 患者的一种非侵入性预后和诊断生物标志物。
